|
|
Blood, 1 November 2005, Vol. 106, No. 9, pp. 3268-3270.
Prepublished online as a Blood First Edition Paper on July 19, 2005; DOI 10.1182/blood-2005-05-1873.
Previous Article | Next Article 
Submitted May 9, 2005
Accepted June 6, 2005
Novel urine hepcidin assay by mass spectrometry
Erwin Kemna*, Harold Tjalsma, Coby Laarakkers, Elizabeta Nemeth, Hans Willems, and Dorine Swinkels
Department of Clinical Chemistry, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
* Corresponding author; email: E.Kemna{at}akc.umcn.nl.
Hepatic peptide hormone hepcidin is the central regulator of iron metabolism and mediator of anemia of inflammation. To date, only one specific immuno-dot assay to measure hepcidin in urine had been documented. Here we report an alternative approach for quantification of hepcidin in urine by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
Peptide peaks were detected corresponding to the three forms of hepcidin normally found in urine. The identity of the peptide peak equivalent to hepcidin-25 was confirmed using synthetic human hepcidin-25.
Validation of our MS data on samples with various hepcidin levels showed a strong correlation with previous immuno-dot assay results (Spearman R = 0.9275, P< 0.0001). Most importantly, this hepcidin assay clearly discriminates between relevant clinical iron disorders.
In conclusion, this novel MS urine hepcidin assay is easy to perform and available to a wide audience. This enables the implementation of hepcidin measurements in large clinical studies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. P.E. Peters, C. M.M. Laarakkers, D. W. Swinkels, and J. F.M. Wetzels
Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate
Nephrol. Dial. Transplant.,
October 23, 2009;
(2009)
gfp546v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Malyszko
Hepcidin Assays: Ironing Out Some Details
Clin. J. Am. Soc. Nephrol.,
June 1, 2009;
4(6):
1015 - 1016.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Browne and D. Reddan
Potential role of bone morphogenetic protein (BMP) signalling as a potential therapeutic target for modification of iron balance
Nephrol. Dial. Transplant.,
January 1, 2009;
24(1):
28 - 30.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Brugnara
An immunoassay for human serum hepcidin at last: Ganz klar?
Blood,
November 15, 2008;
112(10):
3922 - 3923.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ganz, G. Olbina, D. Girelli, E. Nemeth, and M. Westerman
Immunoassay for human serum hepcidin
Blood,
November 15, 2008;
112(10):
4292 - 4297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Collins, M. Wessling-Resnick, and M. D. Knutson
Hepcidin Regulation of Iron Transport
J. Nutr.,
November 1, 2008;
138(11):
2284 - 2288.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Swinkels and J. F. M. Wetzels
Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?
Nephrol. Dial. Transplant.,
August 1, 2008;
23(8):
2450 - 2453.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. H.J.M. Kemna, H. Tjalsma, H. L. Willems, and D. W. Swinkels
Hepcidin: from discovery to differential diagnosis
Haematologica,
January 1, 2008;
93(1):
90 - 97.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T. Howard, U. S. McKakpo, I. A. Quakyi, K. M. Bosompem, E. A. Addison, K. Sun, D. Sullivan, and R. D. Semba
Relationship of Hepcidin with Parasitemia and Anemia among Patients with Uncomplicated Plasmodium falciparum Malaria in Ghana
Am J Trop Med Hyg,
October 1, 2007;
77(4):
623 - 626.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. A. Vanhoutte, C. Laarakkers, E. Marchiori, P. Pickkers, J. F. M. Wetzels, J. L. Willems, L. P. van den Heuvel, F. G. M. Russel, and R. Masereeuw
Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools
Nephrol. Dial. Transplant.,
October 1, 2007;
22(10):
2932 - 2943.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. l. Sullivan
Macrophage Iron, Hepcidin, and Atherosclerotic Plaque Stability
Experimental Biology and Medicine,
September 1, 2007;
232(8):
1014 - 1020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Murphy, D. R. Witcher, P. Luan, and V. J. Wroblewski
Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry
Blood,
August 1, 2007;
110(3):
1048 - 1054.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. H.J.M. Kemna, H. Tjalsma, V. N. Podust, and D. W. Swinkels
Mass Spectrometry-Based Hepcidin Measurements in Serum and Urine: Analytical Aspects and Clinical Implications
Clin. Chem.,
April 1, 2007;
53(4):
620 - 628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ganz
Molecular Control of Iron Transport
J. Am. Soc. Nephrol.,
February 1, 2007;
18(2):
394 - 400.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Tomosugi, H. Kawabata, R. Wakatabe, M. Higuchi, H. Yamaya, H. Umehara, and I. Ishikawa
Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System
Blood,
August 15, 2006;
108(4):
1381 - 1387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Swinkels, M. C.H. Janssen, J. Bergmans, and J. J.M. Marx
Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches
Clin. Chem.,
June 1, 2006;
52(6):
950 - 968.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|